These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16909027)

  • 1. Clinical trials in ALS: what did we learn from recent trials in humans?
    Meininger V
    Neurodegener Dis; 2005; 2(3-4):208-14. PubMed ID: 16909027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials in ALS: an overview.
    Turner MR; Parton MJ; Leigh PN
    Semin Neurol; 2001 Jun; 21(2):167-75. PubMed ID: 11442325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole.
    Paillisse C; Lacomblez L; Dib M; Bensimon G; Garcia-Acosta S; Meininger V
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2005 Mar; 6(1):37-44. PubMed ID: 16036424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of riluzole (Rilutek) treatment on plasma amino acid percentages in amyotrophic lateral sclerosis patients.
    Iłzecka J; Stelmasiak Z; Solski J; Wawrzycki S; Szpetnar M
    Neurol Sci; 2003 Nov; 24(4):290-2. PubMed ID: 14658053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What has changed with riluzole?
    Meininger V; Lacomblez L; Salachas F
    J Neurol; 2000 Dec; 247():19-22. PubMed ID: 11200701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward more efficient clinical trials for amyotrophic lateral sclerosis.
    Cudkowicz ME; Katz J; Moore DH; O'Neill G; Glass JD; Mitsumoto H; Appel S; Ravina B; Kieburtz K; Shoulson I; Kaufmann P; Khan J; Simpson E; Shefner J; Levin B; Cwik V; Schoenfeld D; Aggarwal S; McDermott MP; Miller RG
    Amyotroph Lateral Scler; 2010 May; 11(3):259-65. PubMed ID: 19961263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis.
    Turner MR; Bakker M; Sham P; Shaw CE; Leigh PN; Al-Chalabi A
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Mar; 3(1):15-21. PubMed ID: 12061944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [What are the etiological medical therapies in amyotrophic lateral sclerosis?].
    Dib M
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S215-4S219. PubMed ID: 17128114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Glutamate antagonist].
    Shindo M
    No To Shinkei; 1998 Jul; 50(7):597-605. PubMed ID: 9739517
    [No Abstract]   [Full Text] [Related]  

  • 11. A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis.
    Gordon PH
    Muscle Nerve; 2009 Jun; 39(6):858-60. PubMed ID: 19382169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996-2000.
    Traynor BJ; Alexander M; Corr B; Frost E; Hardiman O
    J Neurol; 2003 Apr; 250(4):473-9. PubMed ID: 12700914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALS clinical trials: do enrolled patients accurately represent the ALS population?
    Chiò A; Canosa A; Gallo S; Cammarosano S; Moglia C; Fuda G; Calvo A; Mora G;
    Neurology; 2011 Oct; 77(15):1432-7. PubMed ID: 21956723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An association study of riluzole serum concentration and survival and disease progression in patients with ALS.
    Groeneveld GJ; van Kan HJ; Lie-A-Huen L; Guchelaar HJ; van den Berg LH
    Clin Pharmacol Ther; 2008 May; 83(5):718-22. PubMed ID: 17898704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riluzole and ALS therapy.
    Hugon J
    Wien Med Wochenschr; 1996; 146(9-10):185-7. PubMed ID: 8873431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective agents for clinical trials in ALS: a systematic assessment.
    Traynor BJ; Bruijn L; Conwit R; Beal F; O'Neill G; Fagan SC; Cudkowicz ME
    Neurology; 2006 Jul; 67(1):20-7. PubMed ID: 16832072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The advance in the research and therapeutic trials of amyotrophic lateral sclerosis].
    Moriwaka F; Tashiro K
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1258-60. PubMed ID: 11464472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis?
    de Carvalho M; Swash M
    Arch Neurol; 2006 Apr; 63(4):557-60. PubMed ID: 16606769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selecting promising ALS therapies in clinical trials.
    Cheung YK; Gordon PH; Levin B
    Neurology; 2006 Nov; 67(10):1748-51. PubMed ID: 17130405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What has changed with riluzole?
    Meininger V; Lacomblez L; Salachas F
    J Neurol; 2000 Dec; 247 Suppl 6():VI/19-22. PubMed ID: 19714404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.